Navigation Links
Insulin Tablets-No More Injections

It may be still far from reality, but the very idea is bound to gladden diabetics. Scientists have announced the possibility of administering insulin orally//, instead of the common injections. At, present insulin is given via injections or via inhalation like Exubera, a recent invention.

Scientists from Taiwan’s National Tsing Hua University have published results of their study in the journal Biomacromolecules.

They detail how blood glucose levels of male lab rats were reduced with the ingestion of a solution containing specially packaged insulin.

The scientists reported using a chemical called chitosan derived from shrimps, crabs or lobsters, to coat insulin. These were then made into very tiny nanoparticles.

The chitosan -shelled insulin was found to escape attack by stomach acids and the particles were very tiny enough to be absorbed into the blood, by cells lining the small intestines. Reduced blood sugar levels of the rats proved the efficacy of the method.

Chitosan, a natural carbohydrate, is both nontoxic and biocompatible.

Insulin, like other protein molecules is attacked and broken down by stomach acids, making oral administration of insulin impossible. Hence this study offers hope for the oral administration of other protein drugs, too.

Says lead researcher Hsing-Wen Sung, "Multiple daily injections of insulin are currently the standard treatment for insulin-dependent diabetic patients. An oral drug would be by far the most convenient and comfortable way of delivering insulin."
ANN
'"/>




Page: 1

Related medicine news :

1. Link between birth weight and Insulin Resistance
2. Easier Methods Required to Screen Insulin Resistance
3. Easier Methods Required to Screen Insulin Resistance
4. Insulin Resistance Linked To Difference In Gender
5. Adopting Easier Methods To Screen Insulin Resistance
6. Another Alternative For Diabetics On Insulin
7. Understanding Insulin Resistance
8. Caffeine Intake May reduce Insulin Sensitivity
9. Junk Food Causes High Level Of Insulin Resistance In Children
10. Increasing Insulin Response In Type 2 Diabetics With New Protein Mixture
11. Elevated Insulin Levels To Influence Levels Of Inflammatory Markers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: